CWP
BEAM icon

Concord Wealth Partners’s Beam Therapeutics BEAM Stock Holding History

Concord Wealth Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-54
Closed -$2K – 251
2022
Q2 		$2K Sell
54
-187
-78% -$7.43K ﹤0.01% 995
2022
Q1 		$14K Buy
241
+66
+38% +$4.33K ﹤0.01% 699
2021
Q4 		$14K Buy
+175
New +$15K ﹤0.01% 707

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concord Wealth Partners's BEAM Position: Q3 2022 in Review

Concord Wealth Partners sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 54 shares — an estimated $2K sold.

Concord Wealth Partners first reported a position in BEAM in Q4 2021 and held it in 3 quarters. The position peaked at $14K in Q1 2022. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Concord Wealth Partners reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 54 Beam Therapeutics shares in Q3 2022, an estimated $2K.
  • Concord Wealth Partners first reported a position in Beam Therapeutics in Q4 2021 and held it in 3 quarters.
  • Concord Wealth Partners's Beam Therapeutics position peaked at $14K in Q1 2022.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Concord Wealth Partners's 13F filing for Q3 2022, filed 10 Nov 2022.